A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study.

Frontiers in oncology（2023）

引用 0|浏览2

暂无评分

摘要

These results support the superiority of lurbinectedin monotherapy for relapsed SCLC over other approved therapies.

查看译文

关键词

lurbinectedin,SCLC,exposure-response,modeling,simulation,Atlantis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要